[1] BAUERSACHS R, BERKOWITZ S D, BRENNER B, et al. Oral rivaroxaban for symptomatic venous thromboembolism[J]. N Engl J Med, 2010, 363(26):2499-2510.
[2] PATEL M R, MAHAFFEY K W, GARG J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011,365(10):883-891.
[3] BAYER A G. Xarelto® (rivaroxaban) Summary of Product Characteristics.[EB/OL]. European Medicines Agency,[2020-01-17]. https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf.
[4] TUCKUVIENE R, CHRISTENSEN A L, HELGESTAD J, et al. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study[J]. J Pediatr, 2011, 159(4):663-669.
[5] RAFFINI L, HUANG Y S, WITMER C, et al. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007[J]. Pediatrics, 2009, 124(4):1001-1008.
[6] CARPENTER S L, RICHARDSON T, HALL M. Increasing rate of pulmonary embolism diagnosed in hospitalized children in the United States from 2001 to 2014[J]. Blood Adv, 2018, 2(12):1403-1408.
[7] GUPTA T, DELHI KUMAR C G, RAMESH KUMAR R, et al. Pediatric thrombotic events: incidence, clinical risk factors and outcome[J]. Indian J Pediatr, 2019, 86(3):241-244.
[8] TETSUHARA K, ISHIGURO A, MICHIHATA N, et al. Pediatric thromboembolism in Japan[J]. The Indian J Pediatr, 2016, 83(10):1077-1081.
[9] MONAGLE P, CHAN A K, GOLDENBERG N A, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141 (2 suppl): e737S-e801S.
[10] MONAGLE P, CUELLO C A, AUGUSTINE C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism[J]. Blood Adv, 2018, 2(22):3292-3316.
[11] PENKOV D, TOMASI P, EICHLER I, et al. Pediatric medicine development: an overview and comparison of regulatory processes in the European Union and United States[J]. Ther Innov Regul Sci, 2017, 51(3):360-371.
[12] CNF1(2010). (中国国家处方集2010年版.化学药品与生物制品卷)[S]. 2010:6-10.
[13] ANDREW M, DAVID M, ADAMS M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE[J]. Blood, 1994, 83(5):1251-1257.
[14] VAN OMMEN C H, HEIJBOER H, BULLER H R, et al. Venous thromboembolism in childhood: a prospective two-year registry in the Netherlands[J]. J Pediatr, 2001, 139(5):676-681.
[15] SABAPATHY C A, DJOUONANG T N, KAHN S R, et al. Incidence trends and mortality from childhood venous thromboembolism: a population-based cohort study[J]. J Pediatr, 2016, 172:175-180.e1.
[16] MONAGLE P, NEWALL F, BARNES C, et al. Arterial thromboembolic disease: a single-centre case series study[J]. J Paediatr Child Health, 2008, 44(1-2):28-32.
[17] ANDREW M, PAES B, MILNER R, et al. Development of the human coagulation system in the full-term infant[J]. Blood, 1987, 70(1):165-172.
[18] ANDREW M, VEGH P, JOHNSTON M, et al. Maturation of the hemostatic system during childhood[J]. Blood, 1992, 80(8):1998-2005.
[19] APPEL I M, GRIMMINCK B, GEERTS J, et al. Age dependency of coagulation parameters during childhood and puberty[J]. J Thromb Haemost, 2012, 10(11):2254-2263.
[20] TOULON P, BERRUYER M, BRIONNE-FRANÇOIS M, et al. Age dependency for coagulation parameters in paediatric populations . Results of a multicentre study aimed at defining the age-specific reference ranges[J]. Thromb Haemost, 2016, 116(1):9-16.
[21] LIPPI G, FRANCHINI M, MONTAGNANA M, et al. Coagulation testing in pediatric patients: the young are not just miniature adults[J]. Semin Thromb Hemost, 2007, 33(8):816-820.
[22] WILLMANN S, BECKER C, BURGHAUS R, et al. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban[J]. Clin Pharmacokinet, 2014, 53(1):89-102.
[23] WILLMANN S, THELEN K, KUBITZA D, et al. Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study[J]. Thromb J, 2018, 16:32. doi: 10.1186/s12959-018-0185-1. eCollection 2018.
[24] ATTARD C, MONAGLE P, KUBITZA D, et al. The in vitro anticoagulant effect of rivaroxaban in children[J]. Thromb Res, 2012, 130(5):804-807.
[25] ATTARD C, MONAGLE P, KUBITZA D, et al. The in-vitro anticoagulant effect of rivaroxaban in neonates[J]. Blood Coagul Fibrin, 2014, 25(3):237-240.
[26] KUBITZA D, WILLMANN S, BECKA M, et al. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study[J]. Thromb J, 2018, 16:31. doi: 10.1186/s12959-018-0186-0. eCollection 2018.
[27] MONAGLE P, LENSING A W A, THELEN K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies[J]. Lancet Haematol, 2019, 6(10):e500-e509.
[28] MARTINELLI I, BUCCIARELLI P, ARTONI A, et al. Anticoagulant treatment with rivaroxaban in severe protein S deficiency[J]. Pediatrics, 2013, 132(5):e1435-e1439.
[29] TRIPODI A, MARTINELLI, CHANTARANGKUL V, et al.Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban[J]. Int J Hematol, 2016, 103(2):165-172.
[30] MENON N, SARODE R, ZIA A. Rivaroxaban dose adjustment using thrombin generation in severe congenital protein C deficiency and warfarin-induced skin necrosis[J]. Blood Adv, 2018, 2(2):142-145.
[31] MARTI'NEZ-MARTI'NEZ I, NAVARRO-FERNA'NDEZ J, STERGAARD A, et al. Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism[J]. Blood, 2012, 120(4):900-904.
[32] VAN BRUWAENE L, HUISMAN A, URBANUS R T, et al. Heparin-resistant thrombosis due to homozygous antithrombin deficiency treated with rivaroxaban[J]. J Pediatr Hematol/Oncol, 2016, 38(8):658-660.
[33] SKRZYPCZYK P, MIZERSKA-WASIAK M, OFIARA A, et al. Pulmonary embolism in a girl with nephrotic syndrome and factor V Leiden-case report[J]. Pol Merkur Lekarski,2018,45(267):114-118.
[34] SAVINO S, BREEN K, HUNT B J. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism[J]. Blood Coagul Fibrinolysis, 2015, 26(4):476-477.
[35] MACK J M, RICHTER G T, CRARY S E. Effectiveness and safety of treatment with direct oral anticoagulant rivaroxaban in patients with slow-flow vascular malformations: a case series[J]. Lymphat Res Biol, 2018, 16(3):278-281.
[36] MA J Y, ZHANG X, LI X F, et al. Thrombotic storm in a 4-year-old boy with a thrombus in the right atriu[J]. Chin J Pediatr(中华儿科杂志), 2018, 56(8):633-634.
[37] SHI Z M, ZHANG T Q, GUO W, et al. A case report of mycoplasma pneumonia-combined pulmonary thromboembolism in child[J]. Clin Focus(临床荟萃), 2019, 34(8):748-751.
[38] MALE C, LENSING A W A, PALUMBO J S, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial[J]. Lancet Haematol, 2020, 7(1):e18-e27.
[39] LANGWIESER N, BERNLOCHNER I, WUSTROW I, et al. Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral post-thrombotic venous obstruction[J]. Phlebology, 2016, 31(6):430-437.
[40] IYENGAR A J, WINLAW D S, GALATI J C, et al. The Australia and New Zealand Fontan Registry: description and initial results from the first population-based Fontan registry[J]. Intern Med J, 2014, 44(2):148-155.
[41] PINA L M, DONG X, ZHANG L, et al. Rivaroxaban, a direct factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: rationale and design of a prospective, randomized trial (the universe study)[J]. Am Heart J, 2019, 213:97-104.
[42] DU X M, ZHU M T, JIAN L Y. Investigation and analysis of clinical application of rivaroxaban[J]. Chin Pharm J(中国药学杂志), 2019, 54(6):489-493.
[43] US Food and Drug Administration.2018 Biological License Application Approvals [EB/OL]. US Food and Drug Administration, [2019-01-13]. https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2018-biological-license-application-approvals.
[44] GOLDENBERG N A, ABSHIRE T, BLATCHFORD P J, et al. Multicenter randomized controlled trial on duration of therapy for thrombosis in children and young adults (the kids-DOTT trial): pilot/feasibility phase findings[J]. J Thromb Haemost, 2015, 13(9):1597-1605.